Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Molecular Partners Ag ADR (NQ: MOLN ) 5.087 +0.017 (+0.34%) Streaming Delayed Price Updated: 3:20 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Molecular Partners Ag ADR < Previous 1 2 3 Next > Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 September 27, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners Reports H1 2024 Corporate Highlights and Financials August 26, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit June 17, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 June 14, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 June 11, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 June 01, 2024 From Molecular Partners Via GlobeNewswire Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program May 16, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action April 29, 2024 From Molecular Partners Via GlobeNewswire Life Science Cares Launches in Switzerland April 19, 2024 First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities From Molecular Partners Via GlobeNewswire Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting April 17, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners Publishes Invitation to Annual General Meeting 2024 March 26, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023 March 14, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners Announces Dismissal of Class Action Lawsuit March 01, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations March 01, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference January 07, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies January 05, 2024 From Molecular Partners Via GlobeNewswire Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences December 14, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting December 10, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS) November 14, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting November 03, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition November 02, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit November 01, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio October 26, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting September 13, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners Reports H1 2023 Corporate Highlights and Financials August 24, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023 June 27, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit June 19, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting May 25, 2023 From Molecular Partners Via GlobeNewswire Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference May 16, 2023 From Molecular Partners Via GlobeNewswire Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy May 11, 2023 From Molecular Partners Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.